Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesCapecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group
British Journal of Cancer, 09/16/09
Garcia–Alfonso P et al. – Combination chemotherapy is standard treatment for metastatic colorectal cancer (MCRC). Capecitabine and irinotecan, given every 2 weeks, as first–line treatment of MCRC is an active regimen with a manageable toxicity profile, even in older patients.
Related Articles
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial
The Lancet Oncology - Online First, 11/11/09
Relevance Score: 94%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 89%
North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 87%
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
Annals of Oncology, 11/16/09
Relevance Score: 85%
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 84%
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Src family tyrosine kinases-driven colon cancer cell invasion is induced by Csk membrane delocalization
Oncogene, 12/16/09
Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression
Genes, Chromosomes and Cancer, 12/16/09
Expression of HIF-1alpha and VEGF in colorectal cancer: Association with clinical outcomes and prognostic implications
BMC Cancer, 12/16/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Port central venous catheters–associated bloodstream infection during outpatient-based chemotherapyTEST
Medical Oncology, 12/17/09
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiformeTEST
Journal of Neuro-Oncology, 12/17/09
CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease
Breast Cancer Research, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor